Rznomics wins FDA RMAT designation for liver cancer gene therapy RZ-001

Rznomics, a Korean company specializing in RNA-based gene therapeutics, announced that RZ-001, its investigational therapy for hepatocellular carcinoma (HCC), has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.

The company also said that an FDA project manager was officially assigned to the program on Thursday U.S. time.

RMAT designation is one of the FDA’s key expedited development programs granted to regenerative medicine therapies targeting serious or life-threatening diseases that demonstrate promising clinical potential in early-stage trials. Therapies receiving RMAT designation can benefit from close consultation with the FDA to accelerate clinical and regulatory strategies, as well as eligibility for regulatory incentives such as priority review, rolling review and accelerated approval pathways.

RZ-001 is a next-generation anticancer therapy based on Rznomics’ proprietary ribozyme-based RNA editing platform technology. The company said the candidate is drawing attention as a potentially innovative treatment capable of overcoming limitations of existing therapies. By enhancing both tumor selectivity and safety, the platform is expected to offer a new therapeutic option for liver cancer patients with limited treatment choices.

RZ-001 received FDA Orphan Drug Designation for HCC in 2024 and Fast Track designation in 2025.

Unlike other expedited programs, RMAT designation requires not only the potential to address unmet medical needs but also supporting preliminary clinical evidence, making it highly selective. Rznomics noted that the FDA’s decision reflects a favorable evaluation of the therapy’s clinical potential and innovation, supported by meaningful early signals observed in interim phase 1b/2a clinical data presented at the 2026 American Association for Cancer Research (AACR) annual meeting in April.

As RMAT designation is granted only to a limited number of promising regenerative medicine therapies in the United States, industry attention is also growing around the possibility of future global licensing-out deals and expanded strategic partnerships.

Hong Sung-woo, vice president of Rznomics, said, “With the RMAT designation, we plan to accelerate discussions with the FDA regarding clinical trial design, chemistry, manufacturing and controls (CMC), and commercialization strategies, while also speeding up development and partnership efforts in the United States.”

Rznomics CEO Lee Seong-wook added, “The RMAT designation for RZ-001 demonstrates that the FDA has recognized the innovation and competitiveness of Rznomics’ RNA editing platform. We will continue focusing our capabilities on global development and commercialization to provide an innovative treatment option in liver cancer, where unmet medical needs remain high.”

RMAT was introduced by the FDA under the 21st Century Cures Act in 2016 to promote the development of innovative regenerative medicine therapies and improve patient access. The designation applies to regenerative medicine products, including gene therapies, cell therapies and tissue-engineered products, intended for serious or life-threatening diseases and supported by preliminary clinical evidence indicating the potential to address unmet medical needs.